Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.

Publication Year: 2023

DOI:
10.1038/s41416-023-02247-5

PMCID:
PMC10241889

PMID:
37024667

Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability raw and processed 3'mrna sequencing data generated in this study have been deposited in the gene expression omnibus database under accession code gse216043 .; the raw and processed dna sequencing data (crispr/cas9 screen) are available in the gene expression omnibus database under accession code gse225852 . a complete list is provided in supplementary fig s4 and supplementary data set s1 .; to further investigate the molecular mechanisms of mln4924 and cisplatin treatment in tgcts the transcriptome of 2102ep as well as jar cells was analysed by 3'mrna sequencing after 2 days of treatment (supplementary data set s1 ). data availability raw and processed 3'mrna sequencing data generated in this study have been deposited in the gene expression omnibus database under accession code gse216043"

Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025